BioSpace News Archive

Biotech Bay

Veeva Pulse Shows Post-Pandemic HCP Access Nearing 80% in Key Specialties Driven by Digital Engagement

Veeva Systems (NYSE: VEEV) today released the latest Veeva Pulse Field Trends Report, the largest and most complete analysis of healthcare professional (HCP) access across the biopharma industry.

November 15, 2022
·
4 min read
Genetown

Casma Therapeutics Raises $46.0 M in Series C Funding

Casma Therapeutics, Inc. today announced the closing of a Series C financing round of $46.0 million.

November 15, 2022
·
2 min read
Lone Star Bio

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx ® -SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors.

November 15, 2022
·
7 min read
Business

Dalia Dawoud, MD, Named Co-Chair of the American Society of Diagnostic and Interventional Nephrology’s 19th Annual Scientific Meeting

Dalia Dawoud, MD, Named Co-Chair of the American Society of Diagnostic and Interventional Nephrology’s 19th Annual Scientific Meeting.

November 15, 2022
·
5 min read
Business

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.

November 15, 2022
·
10 min read
Business

Antibe Reports Q2 2023 Interim Financial and Operating Results

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended September 30, 2022.

November 15, 2022
·
5 min read
Rally Foundation Benefit Bash Raises US $3.36M for Childhood Cancer Research

On Friday, November 11, Rally Foundation for Childhood Cancer Research hosted its 15th Annual Benefit Bash, sponsored by Delta Air Lines, raising more than $3.36 million in critical funding for advances in the fight against childhood cancer.

November 15, 2022
·
3 min read
Pharm Country

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for the treatment of 22q11.2 deletion syndrome (22q).

November 15, 2022
·
7 min read
Business

Garuda Therapeutics Announces Appointment of David DiGiusto, Ph.D., as Chief Technology Officer

Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, announced the appointment of David DiGiusto, Ph.D., as Chief Technology Officer.

November 15, 2022
·
3 min read
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”) today announced that the Company’s lead product candidate, PRP, could enhance the effects of novel therapies like immune checkpoint inhibitors that can have a role in pancreatic cancer treatment.

November 15, 2022
·
5 min read